Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Rating) was the target of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 18,400 shares, a drop of 41.4% from the October 15th total of 31,400 shares. Based on an average daily trading volume, of 103,900 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company's stock are short sold.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Morgan Stanley cut their target price on Xilio Therapeutics from $32.00 to $20.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 10th. Raymond James cut their target price on Xilio Therapeutics from $31.00 to $13.00 and set an "outperform" rating on the stock in a research report on Thursday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Xilio Therapeutics has a consensus rating of "Buy" and an average price target of $16.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP acquired a new position in Xilio Therapeutics during the second quarter worth approximately $417,000. State Street Corp grew its stake in shares of Xilio Therapeutics by 58.5% in the 1st quarter. State Street Corp now owns 93,861 shares of the company's stock valued at $664,000 after purchasing an additional 34,651 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Xilio Therapeutics in the 2nd quarter valued at approximately $220,000. Millennium Management LLC purchased a new position in shares of Xilio Therapeutics in the 2nd quarter valued at approximately $146,000. Finally, Bailard Inc. purchased a new position in shares of Xilio Therapeutics in the 2nd quarter valued at approximately $107,000. Institutional investors and hedge funds own 64.66% of the company's stock.

Xilio Therapeutics Stock Performance

Xilio Therapeutics (NASDAQ:XLO – Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.12). Equities research analysts forecast that Xilio Therapeutics will post -3.49 EPS for the current year.

Xilio Therapeutics Company Profile

(Get Rating)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.

Featured Stories

• Get a free copy of the StockNews.com research report on Xilio Therapeutics (XLO)
• MarketBeat: Week in Review 11/7 – 11/11
• Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
• Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
• Six Flags is a Ride You Don't Want to Get Stuck On
• Hanesbrands May be Signaling a Bad Week for Retail Stocks

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.